The ErbB/HER receptor protein-tyrosine kinases and cancer.
about
The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleusEpidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liverComputational modeling reveals molecular details of epidermal growth factor bindingThe etiologic spectrum of head and neck squamous cell carcinoma in young patientsSide population cells as prototype of chemoresistant, tumor-initiating cellsToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesThe role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancerRegulation of ERBB3/HER3 signaling in cancerHER2 as a therapeutic target in head and neck squamous cell carcinomaOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceThe E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradationDifferences in the binding affinities of ErbB family: heterogeneity in the prediction of resistance mutantsEvolutionary selection of new breast cancer cell-targeting peptides and phages with the cell-targeting peptides fully displayed on the major coat and their effects on actin dynamics during cell internalization.MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET).Phage display selection for cell-specific ligands: development of a screening procedure suitable for small tumor specimens.Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma.Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistryPhage-displayed combinatorial peptide libraries in fusion to beta-lactamase as reporter for an accelerated clone screening: Potential uses of selected enzyme-linked affinity reagents in downstream applications.The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumorsDown-regulation of phospho-non-receptor Src tyrosine kinases contributes to growth inhibition of cervical cancer cells.Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagenEffective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormoneMicroRNA and HER2-overexpressing cancer.The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation.Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.PI4KIIalpha is a novel regulator of tumor growth by its action on angiogenesis and HIF-1alpha regulation.Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.ARAP1 regulates endocytosis of EGFR.Optical fiber-based in vivo quantification of growth factor receptors.γ Sulphate PNA (PNA S): highly selective DNA binding molecule showing promising antigene activity.EGFR signaling in breast cancer: bad to the bone.Markers of bile duct tumorsCytostatic and cytotoxic effects of tyrphostin AG1296 on RMS cellsLoss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networksIn silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common featuresThe Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy.ADAM-mediated amphiregulin shedding and EGFR transactivation.
P2860
Q24295651-9E9A8336-145E-48C6-B921-FAB92DCF3F72Q24680214-2943EA9B-B0E5-4C69-9CB8-1EBF503B25F6Q24814137-4530D4D3-F67A-441C-AA12-364A3AF5D080Q26741362-FE5CC9E0-EAA3-4DB9-BC7F-C5463E8784DCQ26823433-22D5C550-F27A-4758-8E15-9C037F955B06Q26995399-FAF50CD4-D122-4F59-B90C-F786B6A56DEEQ27021738-F5D63B6D-7B22-4B9C-A5AE-F47A148A042BQ27024334-958D6A1B-3303-4D15-BE94-943C714C4561Q27026178-0850BDCC-5233-461E-9E69-9E804DE3F71BQ28077545-4F492C6E-3ECF-49B7-A154-8862482AD746Q28079320-E6974EB2-01F5-49C5-8156-584EA9EB62D1Q28511737-CBCE7523-036E-4E9C-B90A-B9A4A0BA0B0FQ28534601-DF794BA2-8826-49F9-B08D-1CAB10A83BB6Q30497908-685F4B5F-9D58-47B4-B79B-4AC0AE70D8F8Q33211782-DB5988E8-1DDF-4FFE-B438-58ABDBD6C493Q33214333-F0AE5F86-0EF0-485B-AE5E-7DE537B1E572Q33230098-8AAB1DC3-E308-44B8-90ED-6429A6D6A9AAQ33265633-558E0DB1-2A72-481F-948E-D5D777CC1BABQ33398141-B7303378-A873-4A38-8977-567779B4E452Q33538843-A59ADDA8-0DA6-4530-889B-65D351775921Q33595085-7BD40209-E913-4E98-A35E-1B06ED4FD8DBQ33598877-6845BD79-BF96-4EE7-A183-7B25B0BADEA8Q33680681-0C9BDF10-A8C8-441A-870E-531B0F4ED381Q33744931-FC25D4AF-3515-48E1-BB02-950004A10FA1Q33906715-F143A7C1-0338-4CB0-B5B3-9B9A53086152Q33994744-39CC4FD9-2CA2-460D-9760-974ABCDFE8C8Q34048265-FE645369-4DE7-4391-B468-80CC89715070Q34050239-AD9803A9-CEBF-4E31-992B-C4FB94808A00Q34098706-96C26D6F-D0A4-4874-99CE-5DE516C875A8Q34193975-7A9CC1A3-6CA7-4699-8B5D-3673B49776B1Q34222190-5CFA3253-7106-4665-83DA-B99E930264B7Q34226408-631D5FF4-6CC6-4A03-92B2-30BF9CA0F646Q34268989-D6613C49-14B5-4FA6-A51C-A78C8880F3DBQ34348232-B91AC8A0-9A66-48EA-A5C4-2608DCF08DF3Q34628852-BBA16A82-A611-4D9F-A491-FA1D7B89169DQ34780162-0089557D-CA9E-4DC0-88BF-80FACA906656Q34781947-5047057F-B9BA-43EE-9286-6B351364E3AEQ34976925-E41F03A4-FD6A-4B53-B80F-928E65F9A1EFQ35005626-337B3864-2E65-4419-BA27-9FE41FD02B05Q35197805-6F1B606B-F35F-4043-A490-ECE821F7287D
P2860
The ErbB/HER receptor protein-tyrosine kinases and cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The ErbB/HER receptor protein-tyrosine kinases and cancer.
@ast
The ErbB/HER receptor protein-tyrosine kinases and cancer.
@en
The ErbB/HER receptor protein-tyrosine kinases and cancer.
@nl
type
label
The ErbB/HER receptor protein-tyrosine kinases and cancer.
@ast
The ErbB/HER receptor protein-tyrosine kinases and cancer.
@en
The ErbB/HER receptor protein-tyrosine kinases and cancer.
@nl
prefLabel
The ErbB/HER receptor protein-tyrosine kinases and cancer.
@ast
The ErbB/HER receptor protein-tyrosine kinases and cancer.
@en
The ErbB/HER receptor protein-tyrosine kinases and cancer.
@nl
P1476
The ErbB/HER receptor protein-tyrosine kinases and cancer.
@en
P356
10.1016/J.BBRC.2004.04.150
P407
P577
2004-06-01T00:00:00Z